1. Academic Validation
  2. CDK4/6 inhibitors in breast cancer: spotting the difference

CDK4/6 inhibitors in breast cancer: spotting the difference

  • Nat Med. 2021 Nov;27(11):1868-1869. doi: 10.1038/s41591-021-01570-9.
Jose Manuel Perez-Garcia 1 2 3 Javier Cortes 4 5 6 7 8 Antonio Llombart-Cussac 2 3 9
Affiliations

Affiliations

  • 1 Oncology Department, International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain.
  • 2 Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • 3 Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA.
  • 4 Oncology Department, International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain. jacortes@vhio.net.
  • 5 Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. jacortes@vhio.net.
  • 6 Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. jacortes@vhio.net.
  • 7 Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. jacortes@vhio.net.
  • 8 Breast Cancer Research program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. jacortes@vhio.net.
  • 9 Oncology Department, Arnau de Vilanova University Hospital, Valencia, Spain.
Figures
Products